These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

258 related items for PubMed ID: 16563917

  • 1. Vasopressin v(2) receptor blockade with tolvaptan versus fluid restriction in the treatment of hyponatremia.
    Gheorghiade M, Gottlieb SS, Udelson JE, Konstam MA, Czerwiec F, Ouyang J, Orlandi C, Tolvaptan Investigators.
    Am J Cardiol; 2006 Apr 01; 97(7):1064-7. PubMed ID: 16563917
    [Abstract] [Full Text] [Related]

  • 2. Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial.
    Gheorghiade M, Niazi I, Ouyang J, Czerwiec F, Kambayashi J, Zampino M, Orlandi C, Tolvaptan Investigators.
    Circulation; 2003 Jun 03; 107(21):2690-6. PubMed ID: 12742979
    [Abstract] [Full Text] [Related]

  • 3. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia.
    Schrier RW, Gross P, Gheorghiade M, Berl T, Verbalis JG, Czerwiec FS, Orlandi C, SALT Investigators.
    N Engl J Med; 2006 Nov 16; 355(20):2099-112. PubMed ID: 17105757
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Tolvaptan, an oral vasopressin antagonist, in the treatment of hyponatremia in cirrhosis.
    Cárdenas A, Ginès P, Marotta P, Czerwiec F, Oyuang J, Guevara M, Afdhal NH.
    J Hepatol; 2012 Mar 16; 56(3):571-8. PubMed ID: 22027579
    [Abstract] [Full Text] [Related]

  • 6. Treatment of hypervolemic or euvolemic hyponatremia associated with heart failure, cirrhosis, or the syndrome of inappropriate antidiuretic hormone with tolvaptan: a clinical review.
    Nemerovski C, Hutchinson DJ.
    Clin Ther; 2010 Jun 16; 32(6):1015-32. PubMed ID: 20637957
    [Abstract] [Full Text] [Related]

  • 7. Double-blind, placebo-controlled, multicenter trial of a vasopressin V2-receptor antagonist in patients with schizophrenia and hyponatremia.
    Josiassen RC, Goldman M, Jessani M, Shaughnessy RA, Albazzaz A, Lee J, Ouyang J, Orlandi C, Czerwiec F.
    Biol Psychiatry; 2008 Dec 15; 64(12):1097-100. PubMed ID: 18692175
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Improvement in hyponatremia during hospitalization for worsening heart failure is associated with improved outcomes: insights from the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Chronic Heart Failure (ACTIV in CHF) trial.
    Rossi J, Bayram M, Udelson JE, Lloyd-Jones D, Adams KF, Oconnor CM, Stough WG, Ouyang J, Shin DD, Orlandi C, Gheorghiade M.
    Acute Card Care; 2007 Dec 15; 9(2):82-6. PubMed ID: 17573581
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Successful long-term treatment of hyponatremia in syndrome of inappropriate antidiuretic hormone secretion with satavaptan (SR121463B), an orally active nonpeptide vasopressin V2-receptor antagonist.
    Soupart A, Gross P, Legros JJ, Alföldi S, Annane D, Heshmati HM, Decaux G.
    Clin J Am Soc Nephrol; 2006 Nov 15; 1(6):1154-60. PubMed ID: 17699341
    [Abstract] [Full Text] [Related]

  • 13. Assessment of the efficacy and safety of intravenous conivaptan in euvolemic and hypervolemic hyponatremia.
    Zeltser D, Rosansky S, van Rensburg H, Verbalis JG, Smith N, Conivaptan Study Group.
    Am J Nephrol; 2007 Nov 15; 27(5):447-57. PubMed ID: 17664863
    [Abstract] [Full Text] [Related]

  • 14. Pharmacokinetics of conivaptan hydrochloride, a vasopressin V(1A)/V(2)-receptor antagonist, in patients with euvolemic or hypervolemic hyponatremia and with or without congestive heart failure from a prospective, 4-day open-label study.
    Mao ZL, Stalker D, Keirns J.
    Clin Ther; 2009 Jul 15; 31(7):1542-50. PubMed ID: 19695403
    [Abstract] [Full Text] [Related]

  • 15. Hyponatremia, heart failure, and the role of tolvaptan.
    O'Connell JB, Alemayehu A.
    Postgrad Med; 2012 Mar 15; 124(2):29-39. PubMed ID: 22437213
    [Abstract] [Full Text] [Related]

  • 16. Vaptans: a potential new approach for treating chronic hyponatremia in psychotic patients.
    Josiassen RC, Curtis JL, Shaughnessy RA, Filmyer DM, Geboy AG, Skuban N, Ouyang J, Czerwiec F.
    Clin Schizophr Relat Psychoses; 2012 Apr 15; 6(1):21-6. PubMed ID: 22453866
    [Abstract] [Full Text] [Related]

  • 17. Randomized, double blinded, placebo-controlled trial to evaluate the efficacy and safety of tolvaptan in Chinese patients with hyponatremia caused by SIADH.
    Chen S, Zhao JJ, Tong NW, Guo XH, Qiu MC, Yang GY, Liu ZM, Ma JH, Zhang ZW, Gu F.
    J Clin Pharmacol; 2014 Dec 15; 54(12):1362-7. PubMed ID: 24906029
    [Abstract] [Full Text] [Related]

  • 18. Acute hemodynamic effects of tolvaptan, a vasopressin V2 receptor blocker, in patients with symptomatic heart failure and systolic dysfunction: an international, multicenter, randomized, placebo-controlled trial.
    Udelson JE, Orlandi C, Ouyang J, Krasa H, Zimmer CA, Frivold G, Haught WH, Meymandi S, Macarie C, Raef D, Wedge P, Konstam MA, Gheorghiade M.
    J Am Coll Cardiol; 2008 Nov 04; 52(19):1540-5. PubMed ID: 19007589
    [Abstract] [Full Text] [Related]

  • 19. Clinical course of patients with hyponatremia and decompensated systolic heart failure and the effect of vasopressin receptor antagonism with tolvaptan.
    Hauptman PJ, Burnett J, Gheorghiade M, Grinfeld L, Konstam MA, Kostic D, Krasa HB, Maggioni A, Ouyang J, Swedberg K, Zannad F, Zimmer C, Udelson JE, Everest Investigators.
    J Card Fail; 2013 Jun 04; 19(6):390-7. PubMed ID: 23743487
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.